Results 81 to 90 of about 48,562 (198)

Janus Kinase Inhibitors and the Future of Alopecia Areata

, 2022
Alopecia areata (AA) is a common auto-immune condition which results in chronic and recurrent non-scarring patchy hair loss. A continuum of conditions exists from AA to alopecia totalis (AT) and alopecia universalis (AU).
Nailling, Brian B
core  

Successful treatment of the dupilumab-induced psoriatic dermatitis/arthritis and atopic dermatitis with a JAK inhibitor: A case report and literature review

Journal of Allergy and Clinical Immunology: Global
Dupilumab-induced psoriatic dermatitis and arthritis in a patient with atopic dermatitis were effectively managed with upadacitinib, highlighting the use of Janus kinase inhibitors as a possible treatment for biologic therapy side effects.
Misuzu Tsunoda, MD, Takeya Adachi, MD, PhD, Yuuri Nakajima, MD, Yoshihiro Yatomi, MD, Tomoko Shimizu, MD, PhD, Katsuki Nakasute, MD   +5 more
doaj   +1 more source

Baricitinib triggering a central nervous system inflammatory-demyelinating disease: A case report

Multiple Sclerosis Journal - Experimental, Translational and Clinical
Janus kinase inhibitors (JAKis), such as baricitinib, target the Janus kinase/signal transducers and activators of transcription pathway to regulate proinflammatory cytokines and T-helper cell activity, thereby reducing inflammation.
Rozita Khalili, Ahmad A. Toubasi, Meryim Poursheykhi, Francesca Bagnato   +3 more
doaj   +1 more source

Therapeutic effects of janus kinase inhibitors

Janus kinase (JAK) inhibitors are small synthetic molecules which can easily enter the intracellular space and inhibit janus kinases, which renders the janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway to be nonfunctional.
Ntwali, Arnaud
core  

Subcutaneous immunotherapy in a patient taking ofatumumab for multiple sclerosis and upadacitinib for atopic dermatitis

Journal of Allergy and Clinical Immunology: Global
Allergen-specific immunotherapy has not been well-studied in the setting of increasingly common immune system-targeting medications. Subcutaneous immunotherapy may not be contraindicated in patients taking anti-CD20 mAbs antibodies and/or Janus kinase ...
Twan Sia, BA, Leeon Bacchus, BA, Stanley Liu, BS, John Leung, MD   +3 more
doaj   +1 more source

Janus-kinase Inhibitors in Pathogenesis and Management of Chronic Urticaria: A Review of the Literature

, 2023
Background: Chronic urticaria is a long-lasting condition, sometimes with serious comorbidities, severely affecting the quality of life, which makes the patients seek efficient therapies to achieve sustained remissions.
Seyed Karen Hashemitari, Sara Montazeri Namin, Sepideh Darougar   +2 more
core  

Revisiting Janus Kinase Inhibitors in Hospitalized COVID-19: Evidence for Baricitinib’s Superiority and the Absence of a Class Effect

Lei Gu,1,* Jing Lin,2,* Jian Yue,3,* Zeyi Liu,1 Jian-an Huang1 1Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People’s Republic of China; 2Department of ...
Liu Z, Gu L, Lin J, Huang JA, Yue J
core  

Pharmacogenetic biomarkers for predicting therapeutic response to JAK inhibitors in rheumatoid arthritis

Advances in Laboratory Medicine
Rheumatoid arthritis (RA) is a chronic inflammatory disease of immune-mediated origin. Janus kinase inhibitors (JAK inhibitors) have expanded therapeutic options in recent years; however, clinical response varies among patients, and no biomarkers are ...
Plasencia-Rodríguez Chamaida, Novella-Navarro Marta, Valdivieso Shephard Juan Luis, Martínez-Feito Ana, Reche-Yebra Keren, Juárez-García Manuel, Villalba-Yllán Alejandro, Rubio-Lepe Tania S., Arias Pedro, Collada Sánchez Victoria Lucia, Martin-López Susana, Losantos-García Itsaso, Borobia Alberto M., Rosas-Alonso Rocío   +13 more
doaj   +1 more source

From concept to practice: real-world safety of JAK inhibitors in rheumatoid arthritis treatment

Frontiers in Medicine
Janus kinase inhibitors have emerged as highly effective therapies, gaining a prominent role in rheumatoid arthritis treatment. However, by inhibiting multiple cytokine effector pathways, these agents have also raised concerns regarding their safety ...
Karina R. Bonfiglioli
doaj   +1 more source

Naphthyl ketones: A new class of Janus kinase 3 inhibitors

, 2000
Potent inhibition of Janus kinase 3 was found for a series of naphthyl(β-aminoethyl)ketones (e.g. 7, pIC50 = 7.1 ± 0.3). Further studies indicated that these compounds fragment in less than 1 h by retro-Michael reaction in the Jak3 in vitro ELISA assay ...
Tang, Eric, Bowyer, Jonathan, Torr, Vanessa, James, Daniel S., Rankine, Neil, Bamford, Andrea M., Culbert, Eric J., Brown, George R.   +7 more
core   +1 more source